Search

Search Results

• 

  Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients

  M. Romano, I. Pontikaki, M. Gattinara, I. Ardoino, C. Donati, P. Boracchi, P.L. Meroni, V. Gerloni

  278-285

  17-03-2014

  https://doi.org/10.4081/reumatismo.2013.682

  2855

  PDF: 1419
• 

  Possible relationship between certolizumab pegol and arrhythmias: report of two cases

  R. Talotta, F. Atzeni, A. Batticciotto, D. Ventura, P. Sarzi-Puttini

  104-108

  09-09-2016

  https://doi.org/10.4081/reumatismo.2016.869

  1742

  PDF: 1039
• 

  Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study

  R. Talotta, A. Berzi, F. Atzeni, D. Dell'Acqua, P. Sarzi Puttini, D. Trabattoni

  83-89

  09-09-2016

  https://doi.org/10.4081/reumatismo.2016.875

  1987

  PDF: 980

  IL RUOLO DEI LINFOCITI TH9 NELL'ARTRITE REUMATOIDE E NELLA RISPOSTA AL TRATTAMENTO CON INFLIXIMAB.: 576
• 

  Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE)

  G. Carlino, M. Fornaro, L. Santo, R. Bucci, A. Semeraro, L. Quarta, F. D'Onofrio, A. Marsico, C. Zuccaro, P.C. Falappone, D. Mazzotta, F.P. Cantatore, M. Muratore, F. Iannone

  24-30

  01-04-2019

  https://doi.org/10.4081/reumatismo.2019.1154

  1741

  PDF: 1222
• 

  Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab

  Ebru Atalar, Hatice Ecem Konak, Pınar Akyüz Dağlı, Bahar Özdemir Ulusoy, Özlem Karakaş, Kevser Orhan, Rezan Koçak Ulucaköy, Esra Kayacan Erdoğan, Serdar Can Güven, Orhan Küçükşahin, İsmail Doğan, Hakan Babaoğlu, Yüksel Maraş, Şükran Erten, Ahmet Omma, Berkan Armağan

  26-06-2025

  https://doi.org/10.4081/reumatismo.2025.1792

  1959

  PDF: 133
• 

  Are biological drugs safe in pregnancy?

  A. Calligaro, A. Hoxha, A. Ruffatti, L. Punzi

  304-317

  31-03-2015

  https://doi.org/10.4081/reumatismo.2014.798

  3970

  PDF: 2537

• PO:16:231 | Differential clinical features of systemic lupus erythematosus patients on biological therapies: insights from a monocentric cohort Pietro Francesco Pilo, Elisa Bellis, Claudia Garulli, Claudio Cruciani, Marta Saracco, Claudia Lomater, Elena Marucco, Gloria Crepaldi, Valeria Data, Annamaria Iagnocco, Mariele Gatto. | Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, AO Mauriziano, Torino, Italy.

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2043

  81
• 

  Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

  C. Gioia, A. Picchianti Diamanti, R. Perricone, M.S. Chimenti, A. Afeltra, L. Navarini, A. Migliore, U. Massafra, V. Bruzzese, P. Scolieri, C. Meschini, M. Paroli, R. Caccavale, P. Scapato, R. Scrivo, F. Conti, B. Laganà, M. Di Franco

  19-12-2023

  https://doi.org/10.4081/reumatismo.2023.1602

  2037

  PDF: 504
• 

  Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

  M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E.G. Favalli, R. Caporali

  17-07-2023

  https://doi.org/10.4081/reumatismo.2023.1544

  1276

  PDF: 690

• Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort

  E. Molteni, C. Pirone, F. Ceccarelli, C. Castellani, C. Alessandri, M. Di Franco, V. Riccieri, F.R. Spinelli, R. Priori, R. Scrivo, F. Conti

  24-06-2024

  https://doi.org/10.4081/reumatismo.2024.1608

  1868

  PDF: 654

• PO:01:015 | Assessment of the impact of the co-occurrence of psoriasis on the clinical and therapeutic pattern of a single-centre cohort of patients with spondyloarthritis associated with chronic inflammatory bowel disease Andrea Pace¹, Marcella Falconi¹, Alberto Floris^1|2, Leonardo Sichi¹, Francesca Onnis³, Lorenzo Meli³, Raffaela Piras³, Nicola Lutzu³, Federica Olla³, Agnese Favale³, Sara Onali³, Massimo Claudio Fantini³, Matteo Piga^1|2, Alberto Cauli^1|2. | ¹SC Reumatologia, Dipartimento di Scienze Mediche e Salute Pubblica, Università di Cagliari, Cagliari, Italy; ²SC Reumatologia, AOU Cagliari, Cagliari, Italy; ³SC Gastroenterologia, AOU Cagliari, Cagliari, Italy.

  Società Italiana di Reumatologia

  28-11-2025

  https://doi.org/10.4081/reumatismo.2025.2006

  108

• PO:01:003 | Sex-based differences in 2 years treatment outcomes with b/ts-DMARDs in psoriatic arthritis: from real-world evidence to predictive modeling from the Gruppo Italiano Studio Early Arthritis (GISEA) prospective registry Simone Perniola¹, Florenzo Iannone¹, Francesco Paolo Cantatore², Angelo Semeraro³, Leonardo Santo⁴, Roberto Gorla⁵, Alberto Cauli⁶, Roberto Felice Caporali⁷, Bruno Frediani⁸, Rosario Foti⁹, Fabrizio Conti¹⁰, Marco Sebastiani¹¹, Maria Sole Chimenti¹², Roberta Ramonda¹³, Fabiola Atzeni¹⁴, Maurizio Rossini¹⁵, Serena Bugatti¹⁶, Serena Guiducci¹⁷, Giovanni Lapadula¹, Gianfranco Ferraccioli¹⁸, Francesca Romana Spinelli¹⁰, Elisa Gremese¹⁹. | ¹Rheumatology Unit, DiMePReJ, University of Bari, Bari; ²Rheumatology Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria Policlinico Riuniti, Foggia; ³Rheumatology Unit, Martina Franca Hospital; ⁴Rheumatology Unit, ASL BT, P.O. Barletta; ⁵Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia; ⁶Rheumatology Unit, Department of Medical Science and Public Health, University of Cagliari, Monserrato (CA); ⁷Rheumatology Unit, Dipartimento di Reumatologia e Scienze Mediche, ASST PINI-CTO, University of Milano, Milano; ⁸Rheumatology Unit, Azienda Ospedaliero Universitaria Senese, Siena; ⁹Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania; ¹⁰Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and CV Sciences, Sapienza University of Rome, Roma; ¹¹Rheumatology Unit, AUSL Piacenza, University of Parma, Parma; ¹²Rheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Roma; ¹³Rheumatology Unit, DIMED, University of Padua, Padova; ¹⁴Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina; ¹⁵Rheumatology Unit, Department of Medicine, University of Verona, Verona; ¹⁶Division of Rheumatology, Dept. of Internal Medicine and Therapy, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia; ¹⁷Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Firenze, Firenze; ¹⁸Department of Medicine, Catholic University of the Sacred Heart, Fondazione Policlinico Gemelli IRCCS, Roma; ¹⁹Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2000

  112

• A short history of anti-rheumatic therapy. II. Aspirin

  G. Pasero, P. Marson

  148-156

  https://doi.org/10.4081/reumatismo.2010.148

  2583

  PDF: 1589
• 

  Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

  G. Adami, L. Idolazzi, C. Benini, E. Fracassi, A. Carletto, O. Viapiana, D. Gatti, M. Rossini, A. Fassio

  08-05-2023

  https://doi.org/10.4081/reumatismo.2023.1559

  1922

  PDF: 1031

• Safety of anti-TNFa biological drugs

  F. Trotta, G. Valentini

  34-39

  https://doi.org/10.4081/reumatismo.2005.4s.34

  1237

  PDF: 1288

• PO:01:004 | Real-world retention of IL-17 inhibitors in psoriatic arthritis: impact of prior IL-17 exposure across multiple treatment lines in the “BIRRA” multicentre cohort Valentino Paci¹, Alarico Ariani², Eleonora Celletti³, Alberto Lo Gullo⁴, Camilla Mazzanti⁵, Valeria Nucera⁶, Natalia Mansueto⁷, Rosalba Caccavale⁸, Patrizia Del Medico⁹, Antonella Farina¹⁰, Palma Scolieri¹¹, Cecilia Giampietro¹², Olga Addimanda¹³, Riccardo Bixio¹⁴, Maddalena Larosa¹⁵, Viviana Ravagnani¹⁶, Federica Lumetti¹⁷, Aldo Biagio Molica Colella¹⁷, Elena Bravi¹⁷, Rosetta Vitetta¹⁷, Bernd Raffeiner¹⁷, Gilda Sandri¹⁸, Rosario Foti¹⁹, Simone Parisi²⁰, Michele Maria Luchetti Gentiloni¹, Gianluca Moroncini¹. | ¹Clinical Medicine, Department of Clinical and Molecular Sciences, Marche Polytechnic University, AOU delle Marche, Ancona, Italy; ²Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy; ³Rheumatology Unit, Clinica Medica Institute, Ospedale SS. Annunziata di Chieti, G.d'Annunzio University of Chieti, Chieti, Italy; ⁴Rheumatology Unit, ARNAS Garibaldi di Catania, Catania, Italy; ⁵Center for the Diagnosis and Therapy of Autoimmune Rheumagological Diseases, Ospedale Santa Rosa, ASL Viterbo Viterbo Italy; ⁶Rheumatology Outpatient Unit, ASL Novara, Novara, Italy; ⁷Ambulatori di Reumatologia ASL1 Liguria, Imperia Hospitall Imperia Italy; ⁸Department of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Polo Pontino, Roma, Italy; ⁹Rheumatology outpatient clinic - Internal Medicine Unit, Civitanova Marche Hospital, Civitanova Marche, Italy; ¹⁰Internal Medicine Unit, Rheumatology outpatient clinic, Ospedale A. Murri di Fermo, Fermo, Italy; ¹¹Department of Medical Specialties, Nuovo Regina Margherita Hospital, Rome, Roma, Italy; ¹²Rheumatology Outpatient Clinic, Azienda ULSS 6 Euganea, Padova, Padova, Italy; ¹³Rheumatology Unit, Azienda Unità Sanitaria Locale di Bologna -- Policlinico S.Orsola- AOU di Bologna, Bologna, Italy; ¹⁴Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; ¹⁵Division of Rheumatology - Medical Specialties Department, Ospedale La Colletta-Azienda Sanitaria Locale 3, Genova, Italy; ¹⁶Rheumatology Unit, Santa Chiara Hospital APSS Trento Italy; ¹⁷BIRRA - BIologic Retention Rate in chronic Arthritis - study group, Parma, Italy; ¹⁸Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy; ¹⁹Rheumatology Unit, Policlinico San Marco Hospital, Catania, Italy; ²⁰Rheumatology Department, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2001

  118
• 

  Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review

  Eleonora Celletti, Giulio Gualdi, Emanuela Sabatini, Francesco Cipollone, Fabio Lobefaro, Paolo Amerio

  27-01-2025

  https://doi.org/10.4081/reumatismo.2025.1694

  2256

  PDF: 258
• 

  Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

  G. Andrisani, E. Gremese, L. Guidi, A. Papa, M. Marzo, C. Felice, D. Pugliese, A. Armuzzi

  75-78

  27-05-2013

  https://doi.org/10.4081/reumatismo.2013.75

  3065

  PDF: 966

• CO:02:4 | Whole blood hypercoagulable profiles in patients with rheumatoid arthritis Lorenzo Di Luozzo¹, Alessandro Giollo¹, Mariangela Salvato¹, Francesca Frizzera¹, Kiren Khalid¹, Luca Spiezia², Andrea Benetti², Chiara Samà², Paolo Simioni², Andrea Doria¹. | ^1Unità di Reumatologia, Azienda Ospedaliera di Padova; ²Dipartimento di Medicina, Università di Padova, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.1967

  116

• Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the litterature and personal experience

  V. Gerloni, I. Pontikaki, M Gattinara, F. Fantini

  244-261

  https://doi.org/10.4081/reumatismo.2007.244

  1388

  PDF: 1168

• PO:07:099 | Survival on therapy of certolizumab pegol in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: 8-year data from an Italian multicenter register Maria Manara¹, Gilberto Cincinelli^1|2, Marco Fornaro³, Simone Perniola⁴, Elisa Gremese⁵, Chiara Bazzani⁶, Serena Bugatti⁷, Francesca Romana Spinelli⁸, Rosario Foti⁹, Marco Sebastiani¹⁰, Alberto Cauli¹¹, Fabiola Atzeni¹², Giovanni Lapadula¹³, Gianfranco Ferraccioli¹⁴, Fabrizio Conti⁸, Florenzo Iannone³, Roberto Caporali^1|2 | ¹Department of Rheumatology and Medical Sciences, ASST G. Pini-CTO Milano; ²Department of Clinical Sciences and Community Health, University of Milan; ³Department of Precision and Regenerative Medicine and Ionian Area, University of Bari; ⁴Clinical Immunology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; ⁵Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI); ⁶Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia; ⁷Department of Internal Medicine and Therapeutics, Università di Pavia; ⁸Rheumatology Unit, Dipartimento Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza University, Roma; ⁹Rheumatology Unit, San Marco Hospital, Policlinico University of Catania; ¹⁰Rheumatology Unit, AUSL Piacenza, University of Parma; ¹¹UOC di Reumatologia, Dipartimento di Scienze Mediche e Sanità Pubblica, Azienda Ospedaliero-Universitaria di Cagliari; ¹²Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina; ¹³Gruppo Italiano di Studio sulla Early Arthritis, GISEA, Bari; ¹⁴Department of Medicine, Università Cattolica del Sacro Cuore, Fondazione IRCCS Policlinico Gemelli, Roma, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2137

  94